Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3233/JRS-200024 http://scihub22266oqcxt.onion/10.3233/JRS-200024 32474476!7504983!32474476     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+J+Risk+Saf+Med 2020 ; 31 (3): 111-116 Nephropedia Template TP {{tp|p=32474476|t=2020. Risk of using hydroxychloroquine as a treatment of COVID-19 |pdf=|usr=}}{{32474476}} gab.com Text Risk of using hydroxychloroquine as a treatment of COVID-19 JO: Int J Risk Saf Med http://www.kidney.de/pget.php?&tw=1&pmid=32474476 #FOAvip The emerging COVID-19 pandemic poses a threat to the global health care system. Given the lack of antiviral therapies or vaccines for the disease, the antimalarial drug hydroxychloroquine (HCQ) obtained much attention as a treatment for COVID-19. However, there are limited and uncertain clinical data to support the beneficial effect of this drug in COVID-19 treatment. HCQ has several side effects and warnings, including blindness, heart failure, and renal toxicity, even with recommended doses. For severe cases of COVID-19 or in patients with preexisting conditions, administering such a drug could be fatal, particularly when taken at high doses or in combination with other antibiotics. However, further well-designed studies that would address the optimal dose, duration of treatment, possible side effects, and long-term usage outcomes are needed to make the final decision. In this paper, we aim to discuss the risk of using HCQ in treating COVID-19 patients, including its possible side effects. Twit Text FOAVip Risk of using hydroxychloroquine as a treatment of COVID-19 ????Int J Risk Saf Med http://www.kidney.de/pget.php?&tw=1&pmid=32474476 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32474476 #FOAvip English Wikipedia <ref>{{Cite pmid|32474476}}</ref> Risk of using hydroxychloroquine as a treatment of COVID-19 #MMPMID32474476 Alanagreh L; Alzoughool F; Atoum M Int J Risk Saf Med 2020[]; 31 (3): 111-116 PMID32474476show ga The emerging COVID-19 pandemic poses a threat to the global health care system. Given the lack of antiviral therapies or vaccines for the disease, the antimalarial drug hydroxychloroquine (HCQ) obtained much attention as a treatment for COVID-19. However, there are limited and uncertain clinical data to support the beneficial effect of this drug in COVID-19 treatment. HCQ has several side effects and warnings, including blindness, heart failure, and renal toxicity, even with recommended doses. For severe cases of COVID-19 or in patients with preexisting conditions, administering such a drug could be fatal, particularly when taken at high doses or in combination with other antibiotics. However, further well-designed studies that would address the optimal dose, duration of treatment, possible side effects, and long-term usage outcomes are needed to make the final decision. In this paper, we aim to discuss the risk of using HCQ in treating COVID-19 patients, including its possible side effects. |Antimalarials/adverse effects/pharmacology/*therapeutic use[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy[MESH] |Dose-Response Relationship, Drug[MESH] |Drug Administration Schedule[MESH] |Drug Therapy, Combination[MESH] |Humans[MESH] |Hydroxychloroquine/adverse effects/pharmacology/*therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH]Risk of using hydroxychloroquine as a treatment of COVID-19 (epmc).pdf DeepDyve Pubget Overpricing